Delving into the Latest Updates on Yousen Jianheng Biomedical (Shanghai) Co., Ltd. with Synapse

Overview

Tags

Immune System Diseases

Neoplasms

Skin and Musculoskeletal Diseases

Small molecule drug

Biological products

Recombinant protein

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Immune System Diseases	4
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	4
Biological products	2
Recombinant protein	1
Bispecific antibody	1

Top 5 Target	Count

TYK2(Tyrosine-protein kinase 2)	1
KRAS G12D(GTPase KRas G12D)	1

1、主要目的 1）评估健康成人单次服用UA021胶囊后的安全性和耐受性。 2）评估健康成人多次服用UA021胶囊后的安全性和耐受性。 2、次要目的 1）评估健康成人单次和多次服用UA021胶囊后的药代动力学特征。 2）评估食物对健康成人服用UA021胶囊后的药代动力学特征的影响。

[Translation]

1. Primary objectives 1) To evaluate the safety and tolerability of UA021 capsules after a single dose in healthy adults. 2) To evaluate the safety and tolerability of UA021 capsules after multiple doses in healthy adults. 2. Secondary objectives 1) To evaluate the pharmacokinetic characteristics of UA021 capsules after single and multiple doses in healthy adults. 2) To evaluate the effect of food on the pharmacokinetic characteristics of UA021 capsules after taking them in healthy adults.

Start Date-

Sponsor / Collaborator

Yousen Jianheng Biomedical (Shanghai) Co., Ltd.

100 Clinical Results associated with Yousen Jianheng Biomedical (Shanghai) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Yousen Jianheng Biomedical (Shanghai) Co., Ltd.

Login to view more data

100 Deals associated with Yousen Jianheng Biomedical (Shanghai) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Yousen Jianheng Biomedical (Shanghai) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

IND Application

Phase 1

5

1

Phase 2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

UA020	Multiple Myeloma More	Phase 1/2
UA-008	Arthritis More	Phase 1
UA010	Anaphylaxis More	Phase 1
UA011	Solid tumor More	Phase 1
UA022 ( KRAS G12D )	Neoplasms More	Phase 1